<DOC>
	<DOC>NCT01064856</DOC>
	<brief_summary>The objective of this study was to evaluate the efficacy and safety of adalimumab 40 mg administered every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open label (OL) safety and efficacy assessments in participants with non-ankylosing spondylitis (AS), non-psoriatic arthritis (PsA) active peripheral spondyloarthritis (SpA) who have had an inadequate response to &gt;= 2 non-steroidal anti-inflammatory drugs (NSAIDs), or are intolerant to, or have a contraindication for, NSAIDs.</brief_summary>
	<brief_title>Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult participants who had inadequate response to &gt;= 2 nonsteroidal antiinflammatories (NSAIDs) Participants who had arthritis or enthesitis or dactylitis plus: met spondyloarthritis clinical criteria Negative purified protein derivative (PPD) test and Chest XRay performed at Baseline Visit were Negative Ability to administer subcutaneous injections General good health Prior antitumor necrosis factor (TNF) therapy Psoriasis or Psoriatic Arthritis Fulfillment of modified New York criteria for Ankylosing Spondylitis Recent infection requiring treatment Significant medical events or conditions that had put patients at risk for participation Female participants who were pregnant or breastfeeding or considering becoming pregnant during the study History of cancer, except successfully treated skin cancer Recent history of drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>peripheral spondyloarthritis</keyword>
	<keyword>adalimumab</keyword>
	<keyword>humira</keyword>
</DOC>